Nephrocare Health Services reported strong results for FY 2025-26, with consolidated revenue jumping 32.16% to Rs 9,988.45 million and Profit After Tax growing 14.52% to Rs 768.40 million. International operations are a key driver.
Nephrocare Health Services Reports Robust FY25-26 Performance
Consolidated revenue from operations surged by 32.16% to Rs 9,988.45 million in FY 2025-26, up from Rs 7,558.12 million in the prior year. Profit After Tax (PAT) grew by 14.52% to Rs 768.40 million from Rs 670.96 million.
Reader Takeaway: 32% revenue growth and 14.5% PAT rise; technician shortage is a watch point.
What just happened
Nephrocare Health Services Ltd announced its financial results for the fiscal year ending March 31, 2026 (FY 2025-26). The company reported consolidated revenue of Rs 9,988.45 million, a significant increase from Rs 7,558.12 million in FY 2024-25. Consolidated Profit After Tax (PAT) also saw a healthy rise to Rs 768.40 million, up from Rs 670.96 million in the previous year. EBITDA grew by an impressive 39.14% to Rs 2,514.76 million.
Why this matters
These results mark Nephrocare's first full year as a listed entity and demonstrate strong top-line expansion and improved profitability. The significant growth, especially in revenue, indicates successful scaling of its operations and growing market demand for its services. The increasing contribution from international operations diversifies revenue streams.
The backstory
Nephrocare operates a global network of 524 clinics. The company aims to address the large, underserved Chronic Kidney Disease (CKD) population, with only about 7% currently diagnosed. Its strategy involves an asset-light model, expansion into Tier 2/3 cities, and international markets.
What changes now
The company's performance validates its growth strategy. Investors will be keen to see if Nephrocare can sustain its growth momentum, targeting a CAGR of 15% to 20%, while navigating the inherent challenges of the dialysis market.
Risks to watch
A key watch point is the low market penetration of diagnosed CKD patients, indicating both opportunity and the challenge of patient identification. Furthermore, a shortage of technicians, potentially impacting expansion and quality, needs to be managed, possibly through in-house training initiatives like Enpidia.
Peer comparison
(No peer comparison data available in the provided filing text.)
Context metrics (time-bound)
- Total treatments in FY 2025-26: 3.84 million
- International operations contribute ~42% of consolidated revenue.
- Global clinic count: 524
What to track next
Investors should monitor the progress of the Enpidia training program to address staffing needs and the company's success in penetrating under-diagnosed markets. Sustaining the targeted CAGR of 15-20% will also be crucial.